Physician profile
Patrick T Campbell
NPI 1215113154
$102,262.20
in general payments reported to CMS, 2019-2025
45 companies · $6,669 in 2025
The $6,669 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $2,047 · 2021: $3,936 · 2022: $4,863 · 2023: $32K · 2024: $32K · 2025: $6,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $12K · Consulting Fee: $6,745 · Travel and Lodging: $6,500 · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,620.00 |
| Food and Beverage | $12,280.28 |
| Consulting Fee | $6,745.00 |
| Travel and Lodging | $6,499.78 |
| Education | $438.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $25,978.53 | 2019-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $14,902.33 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $13,977.11 | 2019-2025 | Leqvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,648.88 | 2019-2025 | Jardiance |
| Abbott Laboratories | $9,815.78 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Thoratec Heartmate II, Lvas Implant Kit |
| Actelion Pharmaceuticals US, INC. | $9,302.21 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Lilly USA, LLC | $5,227.14 | 2022-2025 | Jardiance, Zepbound |
| Abiomed | $2,294.34 | 2019-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $1,934.36 | 2019-2025 | |
| United Therapeutics Corporation | $1,809.04 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Astrazeneca Pharmaceuticals LP | $1,454.27 | 2020-2025 | Wainua, Farxiga |
| Merck Sharp & Dohme LLC | $970.05 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $582.13 | 2019-2025 | Camzyos |
| Astellas Pharma US INC | $376.82 | 2019-2025 | Cresemba |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $324.07 | 2019-2025 | Lifevest |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $281.29 | 2020-2023 | Protekduo |
| Paragonix Technologies, INC. | $247.96 | 2022-2025 | Baroguard, Lungguard, Sherpapak |
| Novo Nordisk INC | $192.97 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $191.18 | 2019-2021 | |
| Amgen INC. | $179.36 | 2019-2020 | |
| Akcea Therapeutics, INC. | $176.34 | 2019-2020 | |
| Cvrx, INC. | $140.43 | 2024-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $136.44 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $133.54 | 2025 | Attruby |
| Penumbra, INC. | $118.50 | 2022 | |
| Daxor Corporation | $115.78 | 2025 | Bva-100 |
| Sanofi-Aventis U.S. LLC | $104.07 | 2019 | |
| Briohealth Solutions, INC. | $77.03 | 2024 | Briovad |
| Janssen Pharmaceuticals, INC | $75.30 | 2019-2023 | Xarelto |
| Scpharmaceuticals INC. | $62.87 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.69 | 2022-2024 | Livtencity |
| Edwards Lifesciences Corporation | $44.51 | 2019 | |
| Baxter Healthcare | $44.10 | 2019 | |
| Sandoz INC. | $41.87 | 2023-2025 | Treprostinil |
| Eurofins Viracor, LLC | $30.33 | 2022 | |
| Liquidia Technologies, INC. | $29.94 | 2025 | Yutrepia |
| Regeneron Healthcare Solutions, INC. | $29.91 | 2019 | |
| Kestra Medical Technology Services, INC. | $28.00 | 2025 | Assure Wcd |
| Daiichi Sankyo INC. | $27.80 | 2023 | Injectafer |
| Ancora Heart, INC. | $23.00 | 2022 | |
| Abbvie INC. | $21.55 | 2024 | |
| Medtronic, INC. | $20.72 | 2024 | Vitalflow Console |
| Irhythm Technologies, INC. | $19.52 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.